申请人:Ciba-Geigy Corporation
公开号:US05426103A1
公开(公告)日:1995-06-20
The invention relates to macrocyclic lactam derivatives of formula I ##STR1## wherin R is hydrogen or acyl; m is an integer from 4 to 9 inclusive; n is 1 or 2; p is zero, 1 or 2; X is --CONH-- or --NHCO--; Y is S, O or CH.sub.2 ; R.sub.1 is --COOH; or R.sub.1 is ##STR2## in which R.sub.2 is hydrogen, lower alkyl, aryl-lower alkyl, amino-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, mercapto-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, or carboxy-lower alkyl, R.sub.3 is hydrogen or lower alkyl, and q is zero or an integer from 1 to 5 inclusive; or R.sub.1 is ##STR3## in which R.sub.4 is hydrogen, lower alkyl, lower alkoxy, hydroxy or acyloxy, and r is 1 or 2; or R.sub.1 is ##STR4## in which s is 1 or 2; or R.sub.1 is ##STR5## in which R.sub.5 and R.sub.6 independently represent hydrogen, lower alkyl, C.sub.5 - or C.sub.6 -cycloalkyl, (hydroxy-, acyloxy or lower alkoxy-) lower alkyl, carbocyclic or heterocyclic monocyclic aryl, or (hydroxy-, acyloxy- or alkoxy-) lower alkyloxy-lower alkyl; or R.sub.5 and R.sub.6 together with the nitrogen to which they are attached represent pyrrolidino, piperidino, morpholino, piperazino or N-alkylpiperazino; and macrocyclic sulfur and oxygen containing lactam ring isomers in which a CH.sub.2 group of (CH.sub.2).sub.m in formula I is is replaced by O or S, and Y represents CH.sub.2 ; and pharmaceutically acceptable prodrug esters of any above said compound with a free carboxyl group; and pharmaceutically acceptable salts of any said compounds with a free acid or basic salt forming group; pharmaceutical compositions comprising said compounds; methods for the preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.
本发明涉及公式I的大环内
酰胺衍
生物,其中R是
氢或酰基;m是4到9之间的整数;n为1或2;p为零,1或2;X为--CONH--或--NHCO--;Y为S、O或CH.sub.2;R.sub.1为--COOH;或R.sub.1为##
STR2## 其中R.sub.2为
氢、低级烷基、芳基-低级烷基、
氨基-低级烷基、羟基-低级烷基、酰
氧基-低级烷基、低烷
氧基-低级烷基、巯基-低级烷基、低级烷基-(
硫、亚
硫酰或磺酰)-低级烷基或羧基-低级烷基,R.sub.3为
氢或低级烷基,q为零或1到5之间的整数;或R.sub.1为##
STR3## 其中R.sub.4为
氢、低级烷基、低烷
氧基、羟基或酰
氧基,r为1或2;或R.sub.1为##
STR4## 其中s为1或2;或R.sub.1为##
STR5## 其中R.sub.5和R.sub.6独立地表示
氢、低级烷基、C.sub.5-或C.sub.6-
环烷基、(羟基、酰
氧基或低烷
氧基-)低级烷基、
环烷基或杂
环烷基单环芳基,或(羟基、酰
氧基或烷
氧基-)低烷
氧基-低级烷基;或R.sub.5和R.sub.6与它们连接的
氮一起表示
吡咯啉基、
哌啶基、
吗啉基、
哌嗪基或N-烷基
哌嗪基;以及公式I中的(CH.sub.2).sub.m的CH.sub.2基被O或S替换的大环
硫和
氧含有内
酰胺环异构体,Y表示CH.sub.2;以及任何上述化合物的具有自由羧基的药物可接受的前药
酯和具有
自由酸或碱盐形成基团的任何所述化合物的药物可接受的盐;包含所述化合物的制药组合物;制备所述化合物和
中间体的方法;以及通过将所述化合物用于需要此类治疗的哺乳动物的治疗而抑制
中性内肽酶的方法。